Business:
Platform to discover and develop molecular glues - E3 ubiquitin ligases
About:
Triana Biomedicines is using technology to identify “molecular glues” which are small molecules that interact with a disease target protein to change its function. This approach allows for the development of precision medicine that can transform patient lives. Estimates suggest that roughly 85% of disease targets are undruggable. Triana Biomedicines is addressing this with their innovative “molecular glues” which allow them to pursue relevant disease targets that have been deemed undruggable. Specifically, these molecules induce the disease target protein to be “glued” to the components of the cell’s ubiquitin-proteasome system and degraded. Triana Biomedicines is using this targeted protein degradation approach to discover and develop new small molecules with immense therapeutic benefit.